Clinical and Translational Radiation Oncology最新文献

{"title":"Treatment-related toxicity in head and neck cancer patients treated with proton therapy is less common than with conventional radiotherapy","authors":"Efsun Somay , Erkan Topkan , Ugur Selek","doi":"10.1016/j.ctro.2025.100972","DOIUrl":"10.1016/j.ctro.2025.100972","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100972"},"PeriodicalIF":2.7,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining the interpretation of post-radiotherapy urinary and bowel outcomes in prostate cancer: A clinical perspective","authors":"Shengyi Chen, Yuekun Fang, Bin Cheng","doi":"10.1016/j.ctro.2025.100973","DOIUrl":"10.1016/j.ctro.2025.100973","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100973"},"PeriodicalIF":2.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review” [Clin. Translat. Radiat. Oncol. 52 (2025) 100930]","authors":"Elísabet González del Portillo , Alejandro Olivares-Hernández , Luis Corral-Gudino , Laura Corvo Félix , Lorena Bellido Hernández , Luis Posado Domínguez , David León Jiménez , Rogelio González Sarmiento , Edel del Barco Morillo , Emilio Fonseca Sánchez , José Pablo Miramontes-González","doi":"10.1016/j.ctro.2025.100974","DOIUrl":"10.1016/j.ctro.2025.100974","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100974"},"PeriodicalIF":2.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positioning in deep inspiration breath-hold is comparable to free breathing in paediatric patients","authors":"Daniella Elisabet Østergaard , Laura Ann Rechner , Anni Young Lundgaard , Hanne Krogh Rose , Jolanta Hansen , Ivan Richter Vogelius , Lisa Lyngsie Hjalgrim , Marianne C Aznar , Maja Vestmø Maraldo","doi":"10.1016/j.ctro.2025.100975","DOIUrl":"10.1016/j.ctro.2025.100975","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100975"},"PeriodicalIF":2.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143918202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes between proton and photon therapy in nasopharyngeal carcinoma patients: A longitudinal cohort study","authors":"Ching-Nung Wu ,&nbsp;Yu-Ming Wang ,&nbsp;Wei-Chih Chen ,&nbsp;Yun-Hsuan Lin ,&nbsp;Shau-Hsuan Li ,&nbsp;Chung-Feng Hwang ,&nbsp;Bing-Shen Huang ,&nbsp;Chung-Ying Lin ,&nbsp;Sheng-Dean Luo","doi":"10.1016/j.ctro.2025.100971","DOIUrl":"10.1016/j.ctro.2025.100971","url":null,"abstract":"<div><h3>Background and purpose</h3><div>This study aimed to compare patient-reported outcomes (PROs) between intensity-modulated proton therapy (IMPT) and volumetric-modulated arc therapy (VMAT) in treating nasopharyngeal carcinoma (NPC).</div></div><div><h3>Materials and methods</h3><div>A prospective cohort study was conducted at a tertiary care center from 2021 to 2023. Newly diagnosed NPC patients were assessed using the modified 28-item symptom distress scale at seven time points, from baseline (T0) to one year post-radiotherapy (RT) (T6). The analysis focused on symptom changes during the acute phase (T0 to T3 [one month post-RT]) using linear mixed models. Sensitivity analyses incorporated inverse probability treatment weighting and data from non-metastatic patients adhering to survey protocols.</div></div><div><h3>Results</h3><div>IMPT recipients (n = 65) had higher education levels, marital stability, household incomes, and better performance statuses compared to VMAT recipients (n = 36). Oral-related symptoms peaked by the seventh week of RT and declined thereafter. IMPT significantly reduced “oral ulcer” (coefficient: −0.83, SE: 0.27) and “difficulty opening mouth” (coefficient: −0.44, SE: 0.18) symptoms by the seventh week but did not improve “dry mouth.” “Tinnitus” was rated as more distressing than “hearing difficulty,” with no significant differences between IMPT and VMAT for ear-related symptoms. Sensitivity analyses validated these findings.</div></div><div><h3>Conclusion</h3><div>IMPT was associated with reduced severity of specific oral-related symptoms during the acute phase of RT compared to VMAT. While these findings suggest potential benefits of IMPT, baseline differences between groups necessitate cautious interpretation and further validation through randomized studies.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100971"},"PeriodicalIF":2.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of cost-effective multi-sample hypoxia chambers for proton ultra-high dose rate organoid irradiations","authors":"Rutger Jan Cornelis de Koster ,&nbsp;Jeremy Putra Gunawan ,&nbsp;Hans Peters ,&nbsp;Johan Bussink ,&nbsp;Lara Barazzuol ,&nbsp;Marc-Jan van Goethem ,&nbsp;Alexander Gerbershagen ,&nbsp;Robert Paul Coppes ,&nbsp;Stefan Both","doi":"10.1016/j.ctro.2025.100970","DOIUrl":"10.1016/j.ctro.2025.100970","url":null,"abstract":"<div><div>The tissue sparing of ultra-high dose rate irradiation has been partially observed <em>in vitro</em> while controlling oxygen levels. Here, we developed a hypoxia system for high-throughput irradiations that accommodates embedded 3D cultures, such as organoids and spheroids, enabling the study of the effect of oxygen on radiation responses.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100970"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and predictive factors after second stereotactic radiosurgery for refractory trigeminal neuralgia","authors":"Bailey A. Loving ,&nbsp;Jacob F. Oyeniyi ,&nbsp;Siddharth Ramanathan ,&nbsp;Joseph S. Lee ,&nbsp;Hong Ye ,&nbsp;Yastira Ramdas ,&nbsp;Inga S. Grills ,&nbsp;James F. Fontanesi ,&nbsp;Prakash Chinnaiyan ,&nbsp;Daniel K. Fahim ,&nbsp;Daniel B. Michael ,&nbsp;Peter Y. Chen","doi":"10.1016/j.ctro.2025.100969","DOIUrl":"10.1016/j.ctro.2025.100969","url":null,"abstract":"<div><div>ObjectivesThis study evaluates the safety and efficacy of Gamma Knife Stereotactic Radiosurgery (GKSRS) retreatment (T2) for recurrent or refractory trigeminal neuralgia (TN) following an initial SRS treatment (T1).</div></div><div><h3>Methods</h3><div>We analyzed 53 patients who underwent T2 between 2012 and 2018 using a prospectively maintained single institution database. Baseline characteristics, treatment details, and toxicity data were assessed, with pain responses evaluated via Barrow Neurological Institute (BNI) pain intensity scores. Predictors of pain recurrence and chronic sensory toxicity were identified using univariate and multivariable analyses.</div></div><div><h3>Results</h3><div>The median T2 maximum dose was 70 Gy, primarily targeting the cisternal segment (43 %) and retrogasserian zone (RGZ) (34 %). Following T2, 95 % experienced initial pain relief with a 1-month median time to response, and 1-, 2-, and 3-year freedom from pain recurrence of 51 %, 45 %, and 41 %, respectively. Chronic sensory deficits were observed in 62 % of patients, but motor toxicity remained rare (mastication deficit: 2.5 %; facial motor deficit: 5.1 %). RGZ targeting (HR = 3.84, p = 0.02) and single isocenter treatments (HR = 3.85, p = 0.04) were predictive of pain recurrence when compared to dorsal root entry zone (DREZ) targeting and two isocenters, respectively. Affected trigeminal nerve length &lt;11.5 mm was associated with chronic sensory deficits (OR = 7.14, p = 0.02).</div></div><div><h3>Conclusion</h3><div>GKSRS provides effective pain relief and manageable toxicity in retreatment for refractory/recurrent TN. Optimizing parameters, including DREZ targeting and dual-isocenter strategies, can enhance outcomes, while balancing treatment length to mitigate chronic sensory toxicity. Future research should aim at optimizing treatment parameters to maximize pain relief while minimizing toxicity for these patients.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100969"},"PeriodicalIF":2.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Same-Day Magnetic Resonance-Guided Single-Fraction Stereotactic Body Radiation Therapy for Painful Non-Spine Bone Metastases – A Single-Center Study (“BONE SHOT”)","authors":"Sebastian M. Christ ,&nbsp;Eva-Maria Kretschmer ,&nbsp;Michael Mayinger ,&nbsp;Madalyne Day ,&nbsp;Nienke Weitkamp ,&nbsp;Amanda Kristina Moreira ,&nbsp;Stefanie Ehrbar ,&nbsp;Cäcilia S. Reiner ,&nbsp;Marta Bogowicz ,&nbsp;Lotte Wilke ,&nbsp;Stephanie Tanadini-Lang ,&nbsp;Nicolaus Andratschke ,&nbsp;Helena I. Garcia Schüler ,&nbsp;Matthias Guckenberger","doi":"10.1016/j.ctro.2025.100966","DOIUrl":"10.1016/j.ctro.2025.100966","url":null,"abstract":"<div><h3>Introduction and background</h3><div>There is evidence for efficacy of high-dose single-fraction stereotactic body radiotherapy (SF-SBRT) for painful non-spine bone metastases (NSBMs). This study (“BONE SHOT”) assessed feasibility of same-day magnetic resonance-guided (MRg) planning and SF-SBRT delivery, recorded toxicity and assessed efficacy for treating metastatic patients with NSBMs.</div></div><div><h3>Materials and methods</h3><div>Patients with painful (≥3/10 points on a 0–10 numeric rating scale (NRS) for pain) and radiologically confirmed NSBMs from solid organ malignancies were eligible for this prospectively acquired, single-center study. Patients received MRg-SF-SBRT via MR-Linac (ViewRay®) with same-day consultation, consent, planning and treatment. Drop-out rate, procedure times, acute toxicity and pain response were recorded.</div></div><div><h3>Results</h3><div>Between June 2019 and June 2020, 13 patients with 15 NSBMs were treated per protocol. Mean patient age was 64 (range, 30–87) years; most common primary cancer was gastrointestinal malignancies (38.5 %); most commonly treated site was pelvis (53.3 %). All workflows were completed as planned. Median on-table time for contouring, planning and delivery was 65 (range, 57–112) minutes. Treatments were well tolerated; one patient developed “pain flair”; no grade ≥ 3 toxicities were registered. At one week following SBRT, overall and complete pain response rates were 73.3 % and 20.0 %, respectively, which evolved to 66.7 % and 53.3 % at four weeks after SBRT; median pre-treatment pain score was 6 points, which was reduced by a median of 5 points (P = 0.0028) at four weeks.</div></div><div><h3>Conclusion</h3><div>The same-day MRg-SF-SBRT workflow for NSBMs was feasible, safe, and preliminary results indicate promising efficacy, warranting future trials investigating this intervention.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100966"},"PeriodicalIF":2.7,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of simultaneous integrated tumor bed boost and sequential boost during hypofractionated whole-breast irradiation after breast-conserving surgery","authors":"Dan-Qiong Wang ,&nbsp;Yu-Chun Song ,&nbsp;Hao Jing ,&nbsp;Hui Fang ,&nbsp;Yong-Wen Song ,&nbsp;Yue-Ping Liu ,&nbsp;Jing Jin ,&nbsp;Shu-Nan Qi ,&nbsp;Yuan Tang ,&nbsp;Ning-Ning Lu ,&nbsp;Bo Chen ,&nbsp;Ning Li ,&nbsp;Yi-Rui Zhai ,&nbsp;Wen-Wen Zhang ,&nbsp;Xin Liu ,&nbsp;Si-Ye Chen ,&nbsp;Zhuan-Bo Yang ,&nbsp;Guang-Yi Sun ,&nbsp;Xu-Ran Zhao ,&nbsp;Zi-Han Qiu ,&nbsp;Shu-Lian Wang","doi":"10.1016/j.ctro.2025.100967","DOIUrl":"10.1016/j.ctro.2025.100967","url":null,"abstract":"<div><h3>Background and purpose</h3><div>This study aimed to compare the safety and efficacy of simultaneous integrated boost (SIB) and sequential boost (SeB) during hypofractionated WBI.</div></div><div><h3>Materials and methods</h3><div>This study analyzed data from two prospective studies, including 1,132 patients with pT1-3 N0-3 M0 breast cancer, of whom 775 received SIB and 357 received SeB. The prescribed dose was 43.5 Gy in 15 fractions to whole breast and/or nodal region, with either 49.5 Gy in 15 fractions (SIB) or 8.7 Gy in 3 fractions (SeB) delivered to tumor bed. Outcomes analyzed included survival outcomes, treatment-related toxicities, and cosmetic outcomes.</div></div><div><h3>Results</h3><div>The 5-year outcomes were local control rates of 97.8 % vs. 98.8 % (<em>p</em> = 0.12), locoregional control rates of 97.7 % vs. 97.1 % (<em>p</em> = 0.72), disease-free survival of 94.1 % vs. 93.1 % (<em>p</em> = 0.71), overall survival of 97.4 % vs. 97.1 % (<em>p</em> = 0.88), and breast-specific survival of 98.2 % vs. 97.5 % (<em>p</em> = 0.43) for SIB versus SeB, respectively. After stabilized inverse probability of treatment weighting, differences between groups remained non-significant. Rates of fair or poor cosmetic outcomes before and after radiotherapy were lower in the SIB group, but there was no difference in cosmetic deterioration (9.8 % vs. 7.6 %, <em>p</em> = 0.22). Grade 2 or higher toxicities, including skin toxicity, pneumonitis, breast swelling, pain, induration, lymphedema, and shoulder mobility issues, were comparable between groups.</div></div><div><h3>Conclusion</h3><div>SIB is a viable alternative to SeB, offering comparable toxicity profiles and survival outcomes while shortening treatment duration. Longer follow-up is warranted to assess long-term outcomes.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100967"},"PeriodicalIF":2.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143918200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation","authors":"A.E. Verrijssen ,&nbsp;E.J. Van Limbergen ,&nbsp;M. Bellezzo ,&nbsp;H.I. Grabsch ,&nbsp;R. Houben ,&nbsp;D. Goudkade ,&nbsp;J. Melenhorst ,&nbsp;I. Samarska ,&nbsp;G. Paiva Fonseca ,&nbsp;F. Verhaegen ,&nbsp;M. Berbee","doi":"10.1016/j.ctro.2025.100963","DOIUrl":"10.1016/j.ctro.2025.100963","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigates microscopic intramural spread (MIS) after neoadjuvant (chemo)radiotherapy on Total Mesorectal Excision (TME) specimens of rectal cancer patients and explores the necessity of an additional treatment margin for endorectal radiation boosts (for example through contact brachytherapy (CXB)) or local excisions.</div></div><div><h3>Methods</h3><div>A cohort of patients from Maastricht University Medical Center (MUMC + ) treated between 2016 and 2022 was analyzed. Patients underwent MRI, CT scans, and sigmoidoscopy six weeks after radiotherapy, followed by surgery. Pathological analysis of TME specimens, including whole mount macro-cassettes, was performed to measure residual macroscopic tumor and MIS. Fragmented and continuous MIS were recorded parallel and perpendicular to the bowel wall.</div></div><div><h3>Results</h3><div>Out of 54 patients, 37 (69%) exhibited no MIS. MIS was observed in 4/18 (22%) of patients with ycT1-2 tumors and 13/36 (36%) of patients with ycT3-4 tumors. 4 patients (7%) showed continuous MIS and 15 (28%) showed fragmented MIS. No patients with ypT1-2 had MIS.</div></div><div><h3>Conclusions</h3><div>69% of patients do not retain MIS post-neoadjuvant therapy. Knowledge of tumor thickness seems crucial for patient selection for CXB.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100963"},"PeriodicalIF":2.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}